Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499

Mitchell R. Smith, Hailun Li, Leo Gordon, Randy D. Gascoyne, Elisabeth Paietta, Andres Forero-Torres, Brad S. Kahl, Ranjana Advani, Fangxin Hong, Sandra J. Horning

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499'. Together they form a unique fingerprint.

Medicine & Life Sciences